Facebook Linkedin RSS Twitter Youtube
Home 2024

Neurocrine Biosciences

StockWatch: Neurocrine Tumbles as Schizophrenia Data Disappoints
Drug Discovery

StockWatch: Neurocrine Tumbles as Schizophrenia Data Disappoints

Novartis, Voyager Ink Up-to-$1.3B Expansion of Neuro Gene Therapy Collaboration
Drug Discovery

Novartis, Voyager Ink Up-to-$1.3B Expansion of Neuro Gene Therapy Collaboration

Neuroscience Widens Its Investigations of Disease Mechanisms
Insights

Neuroscience Widens Its Investigations of Disease Mechanisms

Takeda, Neurocrine Biosciences Launch up to $2B+ CNS Collaboration
Drug Discovery

Takeda, Neurocrine Biosciences Launch up to $2B+ CNS Collaboration

10 Takeover Targets to Watch This Fall
A-Lists

10 Takeover Targets to Watch This Fall

In $1.9B Alliance, Neurocrine to Develop Voyager Gene Therapies for Parkinson’s, Friedreich’s Ataxia
Featured

In $1.9B Alliance, Neurocrine to Develop Voyager Gene Therapies for Parkinson’s, Friedreich’s Ataxia

FDA Clears Neurocrine’s VMAT2 Inhibitor as First Treatment for Tardive Dyskinesia
Drug Discovery

FDA Clears Neurocrine’s VMAT2 Inhibitor as First Treatment for Tardive Dyskinesia

10 Takeover Targets for 2017
A-Lists

10 Takeover Targets for 2017

Neurocrine Wins $20M from Abbott Related to Elagolix for Endometriosis
Drug Discovery

Neurocrine Wins $20M from Abbott Related to Elagolix for Endometriosis

Abbott Pays $75M to Develop Neurocrine’s GnRH Antagonists in Women’s and Men’s Health
News

Abbott Pays $75M to Develop Neurocrine’s GnRH Antagonists in Women’s and Men’s Health

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.